Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new warrants.
For further information, please contact:
Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 917 749 1494
Last Trade: | US$7.65 |
Daily Change: | -0.67 -8.05 |
Daily Volume: | 21,298 |
Market Cap: | US$286.230M |
March 26, 2025 March 13, 2025 February 19, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load